

**Unaudited Financial Results (Provisional)**  
**For the 3<sup>rd</sup> Quarter and Nine Months Ended 31<sup>st</sup> December 2011**

(Rs. In Lakhs)

Particulars	3 Months ended 31/12/2011	3 Months ended 30/09/2011	3 Months ended 31/12/2010	9 Months ended 31/12/2011	9 Months ended 31/12/2010	Financial Year ended 31/03/2011
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
Net Sale/ Income from Operations	1140.56	1139.70	966.10	3421.54	4654.45	5599.51
Other Operating Income	0.00	0.00	0.00	0.00	0.00	0.00
<u>Expenditure</u>						
Increase/ Decrease in Stock in trade and WIP	0.00	4.47	-17.62	9.51	288.62	302.45
Purchase / Cost of Operations	1089.90	1088.55	938.07	3269.67	4203.80	5094.09
Employee Cost	6.34	6.31	7.98	19.76	22.90	30.04
Depreciation	9.30	9.30	10.27	27.90	30.80	41.06
Other Expenditure	14.95	15.86	13.97	41.93	41.94	53.09
<b>Total</b>	<b>1120.49</b>	<b>1124.49</b>	<b>952.67</b>	<b>3368.77</b>	<b>4588.06</b>	<b>5520.73</b>
<b>Profit from operations before other income, interest and exceptional items</b>	<b>20.07</b>	<b>15.21</b>	<b>13.43</b>	<b>52.77</b>	<b>66.39</b>	<b>78.78</b>
Other Income	3.06	3.02	1.56	9.01	5.98	12.62
<b>Profit before interest and exceptional items</b>	<b>23.13</b>	<b>18.23</b>	<b>14.99</b>	<b>61.78</b>	<b>72.37</b>	<b>91.40</b>
Interest	0.00	0.00	0.00	0.00	0.00	0.00
<b>Profit after interest but before exceptional items</b>	<b>23.13</b>	<b>18.23</b>	<b>14.99</b>	<b>61.78</b>	<b>72.37</b>	<b>91.40</b>
Exceptional items	0.00	0.00	0.00	0.00	0.00	0.00
<b>Profit (+)/ Loss (-) from ordinary activities before tax</b>	<b>23.13</b>	<b>18.23</b>	<b>14.99</b>	<b>61.78</b>	<b>72.37</b>	<b>91.40</b>
Tax Expense	0.00	0.00	0.00	0.00	0.00	(0.08)
<b>Net Profit (+)/ Loss (-) from Ordinary Activities after tax</b>	<b>23.13</b>	<b>18.23</b>	<b>14.99</b>	<b>61.78</b>	<b>72.37</b>	<b>91.48</b>
Extraordinary Item (net of tax expenses)	0.00	0.00	0.00	0.00	0.00	0.00
<b>Net Profit (+)/ Loss (-) for the period</b>	<b>23.13</b>	<b>18.23</b>	<b>14.99</b>	<b>61.78</b>	<b>72.37</b>	<b>91.48</b>
Paid-up Equity Share Capital (Face Value of the Share shall be indicated)	1099.20	1099.20	1099.20	1099.20	1099.20	1099.20
Face Value of Equity Shares (Rs.)	1.00	1.00	1.00	1.00	1.00	1.00
Reserve excluding Revaluation Reserves as per Balance Sheet of previous year						664.42
<u>Earning Per Share (EPS)</u>						
(a) Basic & Diluted EPS before Extraordinary items for the period, for the year to date and for the previous year (not to be annualised)	0.02	0.02	0.01	0.06	0.07	0.08



**Corporate Office :**

A-56/A Lajpat Nagar - II, 1st Floor, New Delhi - 110 024  
 Tel: +91-11-41720778 Fax: +91-11-29847741

Email: info@mavensbiotech.com - Website: www.mavensbiotech.com

**Registered Office :**

Sagar Estate, Suite No. 21, Grd, 2 N. C. Dutta Sarani,  
 Kolkata - 700 001 Tel: +91-33-22623056

(b) Basic & Diluted EPS after Extraordinary items for the period, for the year to date and for the previous year (not to be annualised)	0.02	0.02	0.01	0.06	0.07	0.08
<b>Public Shareholding</b>						
- No. of shares	74700010	74700010	74700010	74700010	74700010	74700010
- Percentage of shareholding	67.96%	67.96%	67.96%	67.96%	67.96%	67.96%
<b>Promoters and promoter group Shareholding</b>						
a) Pledged/ Encumbered						
- Number of shares	0	0	0	0	0	0
- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	0%	0%	0%	0%	0%	0%
- Percentage of shares (as a % of the total share capital of the company)	0%	0%	0%	0%	0%	0%
b) Non-encumbered						
- Number of Shares	35219990	35219990	35219990	35219990	35219990	35219990
- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	100%	100%	100%	100%	100%	100%
- Percentage of shares (as a % of the total share capital of the company)	32.04%	32.04%	32.04%	32.04%	32.04%	32.04%

**Quarterly Reporting Segment wise Revenue, Results and Capital Employed under Clause 41 of the Listing Agreement**

(Rs. In Lakhs)

Particulars	3 Months ended 31/12/2011 Unaudited	3 Months ended 30/09/2011 Unaudited	3 Months ended 31/12/2010 Unaudited	9 Months ended 31/12/2011 Unaudited	9 Months ended 31/12/2010 Unaudited	Financial Year ended 31/03/2011 Audited
<b>Segment Revenue</b>						
(Net Sale/ income from each segment)						
Sale of Commodities & Agro Products	1139.54	1137.77	965.02	3418.59	4650.49	5595.55
IT Business	1.02	1.93	1.08	2.97	3.96	3.96
Unallocated	0.00	0.00	0.00	0.00	0.00	0.00
<b>Total</b>	<b>1140.56</b>	<b>1139.70</b>	<b>966.10</b>	<b>3421.54</b>	<b>4654.45</b>	<b>5599.51</b>
Less : Inter Segment Revenue	0.00	0.00	0.00	0.00	0.00	0.00
<b>Net Sales/ Income from operations</b>	<b>1140.56</b>	<b>1139.70</b>	<b>966.10</b>	<b>3421.54</b>	<b>4654.45</b>	<b>5599.51</b>
<b>Segment Results</b>						
(Profit / Loss before tax and interest from each segment)						
Sale of Commodities & Agro Products	23.11	18.20	17.27	61.73	79.55	100.67
IT Business	0.07	0.15	0.03	0.22	0.14	0.14



**Corporate Office :**

A-56/A Lajpat Nagar - II, 1st Floor, New Delhi - 110 024  
Tel: +91-11-41720778 Fax: +91-11-29847741

Email: info@mavensbiotech.com Website: www.mavensbiotech.com

**Registered Office :**

Sagar Estate, Suite No. 21, Grd, 2 N. C. Dutta Sarani,  
Kolkata - 700 001 Tel: +91-33-22623056

Less : Interest	0.00	0.00	0.00	0.00	0.00	0.00
Less : Inter Segment Income	0.00	0.00	0.00	0.00	0.00	0.00
Less: Unallocable Expenditure	0.05	0.12	2.31	0.17	7.32	9.41
<b>PBT</b>	<b>23.13</b>	<b>18.23</b>	<b>14.99</b>	<b>61.78</b>	<b>72.37</b>	<b>91.40</b>

### Segment Capital Employed

Fixed Assets used in the company's business or liabilities have not been identified to any of the reportable segments, as the fixed assets and services are used interchangeably between segments. The management believes that it is currently not practicable to furnish segmental disclosures relating to total assets and liabilities.

### Notes:

1. The above Unaudited financial results were reviewed by the audit committee and taken on record by Board of Directors at their meeting held on 30/01/2012.
2. Segment Revenue: Revenue for this quarter/ nine months comes from two activities, i.e., Sale of Commodities & Agro Products and IT Business.
3. The above results have been subjected to "Limited Review" by the Statutory Auditor of the Company pursuant to Clause No.41 of the Listing Agreement. An unqualified report has been issued by them thereon.
4. Provision for taxations will be made at the end of the year.
5. There were no complaints pending at the beginning of the quarter and 2 complaints were received from the investors during the quarter and resolved.
6. Figures of the previous period have been regrouped wherever necessary.

Date: 30/01/2012  
Place: Kolkata



By Order of the Board  
For MAVENS Biotech Limited

Sd/-  
Director